Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.093 AUD 3.33%
Market Cap: 111.7m AUD

ALA's latest stock split occurred on Jul 7, 2020

The company executed a 72-for-61 stock split, meaning that for every 61 shares held, investors received 72 new shares.

Before the split, ALA traded at 0.0305 per share. Afterward, the share price was about 0.034.

The adjusted shares began trading on Jul 7, 2020. This was ALA's 6th stock split, following the previous one in Nov 14, 2019.

Last Splits:
Jul 7, 2020
72-for-61
Nov 14, 2019
1-for-25
Nov 13, 2019
1-for-25
Jun 5, 2019
20-for-19
Jul 6, 2018
12-for-11
Pre-Split Price
0.0305 0.0305
Post-Split Price
0.034
Before
After
Last Splits:
Jul 7, 2020
72-for-61
Nov 14, 2019
1-for-25
Nov 13, 2019
1-for-25
Jun 5, 2019
20-for-19
Jul 6, 2018
12-for-11

Arovella Therapeutics Ltd
Stock Splits History

ALA Stock Splits Timeline
Jul 7, 2020
Jul 7, 2020
Split 72-for-61
x1.1803278688525
Pre-Split Price
0.0305 0.0305
Post-Split Price
0.034
Before
After
Nov 14, 2019
Nov 14, 2019
Split 1-for-25
/0.04
Pre-Split Price
0.0424 0.0424
Post-Split Price
0.0466
Before
After
Nov 13, 2019
Nov 13, 2019
Split 1-for-25
/0.04
Pre-Split Price
0.0424 0.0424
Post-Split Price
0.0424
Before
After
Jun 5, 2019
Jun 5, 2019
Split 20-for-19
x1.0526315789474
Pre-Split Price
0.1006 0.1006
Post-Split Price
0.1059
Before
After
Jul 6, 2018
Jul 6, 2018
Split 12-for-11
x1.0909090909091
Pre-Split Price
0.1107 0.1107
Post-Split Price
0.1006
Before
After
Jun 1, 2009
Jun 1, 2009
Split 123-for-112
x1.0982142857143
Pre-Split Price
N/A
Post-Split Price
0.2767
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Arovella Therapeutics Ltd
Glance View

Market Cap
110.5m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.01 AUD
Overvaluation 89%
Intrinsic Value
Price
Back to Top